Upcoming Webinar: Ovarian Cancer Awareness and Management

Submitted by PatientsEngage on 28 March 2022

This webinar is not just for Ovarian Cancer survivors but also for survivors of breast cancer, uterine cancer, colorectal cancer and all women at risk of Ovarian Cancer.

Ovarian Cancer is a difficult to diagnose cancer. So it is very important for us to be aware of the surprising symptoms of Ovarian cancer. We must also know the factors that increase risk.
Additionally, in COVID times, it is important to understand how to continue treatment and when you should vaccinate.

We bring together a panel of
Dr. Shyam Aggarwal, Chairman Medical Oncology, Sir Gangaram Hospital, New Delhi
Dr. Nidhi Tandon, Consultant Medical Oncology Narayana Health, Bengaluru
Dr. Vivek Agarwala, Medical Oncologist, Narayana Superspeciality Hospital, Kolkata

In the video (recording link below) we talk about:

What is ovarian cancer and who is at risk of ovarian cancer? is it hereditary
What are the early signs or symptoms of ovarian cancer?
Who should you consult when you have symptoms
What is the difference between cyst and cancer and how to differentiate between the two
Does removal of ovaries reduce lifespan?
What are the treatment options after diagnosis of ovarian cancer?
What risks should patients be aware of and role of chemo before or after surgery
If you have ovarian cancer can you also get breast cancer?
Even during covid cancer treatment cannot be postponed
Are video consults useful
Can cancer patients undergo Covid vaccination

Community

Women's Health and Pregnancy

Condition

Changed

Mon, 03/28/2022 - 16:07

Stories

Breast cancer drug Perjeta appears to extend patients lives

According to reports from clinical trials, Roche’s breast cancer drug Perjeta displays “unprecedented” life-extending effects, helping patients live an average of 15.7 months longer than they would on chemotherapy and an older drug. 15.7 months is a significant amount of time for metastatic breast cancer patients, who are, on average, given two to three years to live after their diagnosis. Perjeta, then, has the capacity to increase that time by 50 to 75 percent. http://www…
If You Suffer From Endometriosis, Better Help May Be Coming

New drug combo shows promise in relieving pain, symptoms A recent clinical study, conducted at the University of Bath in England with women of reproductive age, demonstrated great potential of a new drug combination. The two drugs are E2MATE – created in the university’s Department of Pharmacy & Pharmacology – and norethindrone acetate, or traditional progesterone. Researchers must test the drug combination further in human trials to confirm that it will be an effective treatment of…
Did you know that womb cancer is the fourth most common cancer in women ?

My cancer could have been caught earlier if I had been alerted about spotting between periods, heavy periods and watery blood between periods as the main symptoms of womb cancer,” she says. But when she asked NHS Choices whether there should be mention of womb cancer on the menopause pages, she received the following reply: “The problem with adding a warning about womb cancer to the menopause pages is that it may cause unnecessary panic.” And this, says Widschwendter, is the nub of the problem…
U.S. FDA Approves New Indication for the Use of Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

The FDA initially approved XTANDI, an oral, once-daily androgen receptor inhibitor, in August 2012 for use in patients with metastatic CRPC who previously received docetaxel (chemotherapy). The new indication approves XTANDI for use in men with metastatic CRPC who have not received chemotherapy. Metastatic CRPC is defined as a cancer that has spread beyond the prostate gland and has progressed despite treatment to lower testosterone (i.e., with a gonadotropin-releasing hormone (GnRH) therapy or…
Heal Your Cancer

Don’t fight cancer, heal it by attending to body, mind and spirit, says surgical oncologist Dr Vishal Rao. A child developing from an embryo in a mother’s womb is, in reality, a set of rapidly multiplying cells. But they are controlled and regulated. So, we choose to ‘love’ those cells. But when another set of cells multiply rapidly within our body, albeit haphazardly, we call it ‘Cancerous’! These cells are not foreign cells that have made an appearance from outside,…
“I was open to anything, just trying to find things to help me stay alive,” said Geoffrey Boycott

Geoffrey Boycott describes how counting off his radiotherapy sessions like runs in cricket and Feng Shui helped him survive cancer http://www.telegraph.co.uk/sport/cricket/11080199/Geoffrey-Boycott-reve…
FDA approves first non-invasive home based DNA screening test for colorectal cancer

The U.S. Food and Drug Administration approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. Cologuard offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home. Colorectal cancer was the third most…
Mayo Clinic partners with IBM to match Cancer Patients with Clinical Trials

Mayo Clinic unveiled today a partnership with IBM to harness the power of its Watson supercomputer to match patients with the right clinical trials. Starting early next year, Watson will initially enroll patients with breast, colorectal and lung cancers based on eligibility. There are 170,000 ongoing clinical trials around the world, however, according to the Center for Information and Study on Clinical Research Participation, only 6% are completed on time. Enrolling patients in the…
FDA approves first use of novel immune system drug for cancer

This new class of drugs unleashes the body's immune system to fight tumors. This seems to solve a century-old mystery of how cancerous cells manage to evade the body's immune system. The drug which Merck will sell under the name of Keytruda was approved by patients with advanced melanoma who have exhausted other therapies. http://www.nytimes.com/2014/09/05/business/merck-wins-approval-of-novel-immune-system-drug-for-cancer.html?emc=eta1
Breast cancer specialist reports advance in treatment of triple-negative breast cancer that disproportionately affects younger women

We hope that this means fewer women will relapse and die of their cancer, though the study is not large enough to prove this conclusively. Of the two agents we studied, we are more encouraged by the results from the addition of carboplatin, since it was associated with fewer and less concerning additional side effects than bevacizumab," Sikov explains. William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's…